Dublin, Sept. 15, 2017 -- The "Drug Discovery Outsourcing Global Market - Forecast to 2025" report has been added to Research and Markets' offering.
Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Almost all the major Pharmaceutical companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Nowadays, the big pharma relies more on CRO's for drug discovery capabilities to stock up their pipelines.
The growth is attributed to the increase in biologics R&D spending and lesser approval time, on the other hand factors such as tedious discovery process and high cost associated are restraining the biologics growth.
The pharmaceutical companies should consider several factors before finalizing a CRO partner like therapeutic area expertise, business model, scientific pool, infrastructure, data security, IP policies and last but not least cost-efficiency. Along with CRO's expertise on drug discovery, the most important aspect the pharma companies look for in a CRO is a verified track record of successfully working in the discovery program of relevant therapeutic area.
Key Topics Covered:
1 Introduction
2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies
3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.3 Certifications
3.4 DD Indicators
3.5 Pharma R&D Exp & Intensity
4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global FTE Rates
4.3 Regional Revenues Vs FTE
4.4 Key players (Revenue Per Employee, Customers, Deals & TA Pie Chart, Collaboration Outcomes)
5 Leading Players
5.1 Overview
5.2 Capabilities
5.3 Therapeutic Area
5.4 Business Models
5.5 Collaborations
5.6 Acquisitions
6 Marketing Strategies
6.1 Conferences
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online RPFS
6.5 Networking Websites
6.6 Clusters
6.7 Other Marketing Strategies
Companies Mentioned
- Advinus
- AMRI Global
- Aurigene
- Bioduro LLC
- Charles River Laboratories (CRL)
- Chempartner
- Evotec
- GVK Biosciences
- Jubilant Biosys
- Pharmaron Inc.
- Shanghai Medicilon
- Sundia Meditech Co. Ltd.
- Syngene
- TCG Lifesciences
- Wuxiapptec
For more information about this report visit https://www.researchandmarkets.com/research/r7jgns/drug_discovery
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Drug Discovery


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



